New pyridazinone derivatives with vasorelaxant and platelet antiaggregatory activities

New platelet aggregation inhibitors based on pyridazinone moiety

“…In addition, in the fused-pyridazinone series, the furopyridazinone derivative 6a showed low activity (IC 50 value of 70.57 ± 15.55 mM) as compared with the corresponding monocyclic analogs [10].…”

“…A total of thirteen new pyridazinone derivatives (4aee, 5aee and 6aec) were tested in order to determine if the new monocyclic and bicyclic analogs show similar antiplatelet activity to that exhibited by the C6-substituted pyridazinone derivatives (3aec) previously reported [10]. Table 1 shows the IC 50 values against collagen for the new analogs and 3aec derivatives [10]. They were obtained from experiments conducted at concentration intervals of 0.5e5 mM or 10e100 mM, depending on the compound.…”

“…Most of the previously designed compounds inhibited platelet aggregation induced by collagen in the low mM range (1.80e69.6), being silyl ethers and N,O-dibenzyl derivatives the most active compounds. Many of them also showed a moderate vasorelaxant effect [10].…”

Synthesis and Antitubercular Activity of Pyridazinone Derivatives

“…The compounds, 1 and 2, were synthesized according to the reported method [14]. (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18). Compounds (3-18) were synthesized from 3-(4-chloro/methyl benozyl) propionic acid (1,2) following literature method [14].…”

“…Differently substituted pyridazinones have been found to have potential antibacterial, antifungal and antiviral including anti-HIV activities [1][2][3][4]. Various 3-(2H)-pyridazinone derivatives have shown anticancer [4], analgesic & anti-inflammatory [4][5][6], anticonvulsant [7], cardiotonic & hypotensive [8,9] and antiulcer activities [10].…”